CTMC
Trending Articles
Related Content
Manufacturing
Investing in a manufacturing infrastructure to harness tumour-infiltrating lymphocytes (TILs) for cancer treatment
In this article, Dr Chantale Bernatchez, Director of Process Development at CTMC, highlights the need for a standardised TIL manufacturing process that facilitates co-ordination between labs, clinics and production sites. She emphasises the value of using the lessons learned from implementing CAR-T therapy to streamline the introduction of new TIL treatments to the patients who need them